MARKETVUE® REPORT: 60% of ANCA-associated vasculitis U.S. clinicians report Amgen’s Tavneos’ steroid-sparing ability and remission times as impressive

AdComm experts were split on whether to approve Amgen’s Tavneos (avacopan) in 2021, however, this sentiment has not been reflected in physician uptake and perception of Tavneos which has been positive, according to REACH Market Research. NEWTON, Mass., March 1, 2023 /PRNewswire/ –…